POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immune cells take aim at Post-Transplant virus
Disease control Recruiting nowThis early-stage study tests a new treatment using specially grown immune cells (EBV-AST cells) to fight EBV infections in people who have had a stem cell transplant. The trial will enroll 18 adults with persistent EBV in their blood. Researchers will test three different doses t…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 23, 2026 12:04 UTC
-
New hope for transplant patients: targeted combo aims to beat rare cancer
Disease control Recruiting nowThis study tests a combination of two drugs, polatuzumab vedotin and rituximab, as a first treatment for a rare blood cancer that can occur after organ or stem cell transplants. The goal is to see if this combo is safe and works better than current options, possibly avoiding the …
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Engineered immune cells take on Epstein-Barr virus in transplant patients
Disease control Recruiting nowThis early-phase study tests a new treatment for Epstein-Barr virus (EBV) infection that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) designed to find and destroy EBV-infected cells. Up to 18 adult patients who hav…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 22, 2026 12:01 UTC
-
New targeted therapy shows promise for Tough-to-Treat lymphomas
Disease control Recruiting nowThis study tests a drug called loncastuximab tesirine in adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug works like a smart bomb, attaching to a marker on cancer cells and delivering chemotherapy directly to them. The main goal is to …
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 11, 2026 12:08 UTC